Arjungenin

Arjungenin at a Glance

Arjungenin is an oleanane-type pentacyclic triterpenoid — chemically 2,3,19,23-tetrahydroxyolean-12-en-28-oic acid — from the bark of arjuna (Terminalia arjuna), the South-Asian tree with a long cardiac-tonic reputation. It sits in the same family of bark triterpenes as arjunolic acid and arjunic acid, but its defining role is structural: arjungenin is the sapogenin (aglycone) that carries the sugar in the bark’s saponins, chiefly arjunglucoside I and arjunetin.

As an isolated molecule the evidence is genuinely thin. The real, compound-specific signal is a single in-vitro study showing moderate free-radical scavenging and inhibition of an inflammatory neutrophil oxidant ^{2Reference 2Pawar RS · 2005Effect of oleanane triterpenoids from Terminalia arjuna — a cardioprotective drug — on the process of respiratory oxyburstView study →}, plus an in-silico-plus-cell study framing it as a metabolic (FXR-agonist) candidate ^{6Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →} and an in-silico acetylcholinesterase-docking result ^{7Reference 7Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}. There are no human trials of arjungenin, and the clinical reputation of arjuna belongs to the whole bark extract, not to this one molecule.

The honest headline: arjungenin is best understood as a minor building block of arjuna’s saponin chemistry with a promising but preliminary isolate profile, undercut by the usual triterpene problem of poor oral absorption.

Arjungenin, the Arjuna Sapogenin

The point of this molecule is its place in arjuna’s triterpene architecture. Arjuna bark makes a small set of oleanane triterpene acids — arjunolic acid (the most abundant, ~0.5% w/w), arjunic acid, and arjungenin (~0.3% w/w) — and then glucosylates them at the C-28 carboxyl to form the corresponding saponin esters ^{3,8Reference 3Kalola J · 2006Extraction and TLC densitometric determination of triterpenoid acids (arjungenin, arjunolic acid) from Terminalia arjuna stem bark without interference of tanninsView study →Reference 8Vyas P et al. · 2025UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna treeView study →}. Arjungenin is the aglycone of arjunglucoside I; its close relative arjunetin is the C-28 glucosyl ester of arjunic acid. In other words, much of the arjungenin in the bark is not free but locked up as the sugar-bearing saponin, released only on hydrolysis ^{1Reference 1Honda T et al. · 1976Arjungenin, arjunglucoside I, and arjunglucoside IIView study →}.

Structurally it differs from the better-known arjunolic acid by one extra hydroxyl: arjungenin is the 2,3,19,23-tetrahydroxy oleanane acid, arjunolic acid the 2,3,23-trihydroxy one. That added 19-hydroxyl makes arjungenin more polar than arjunolic or arjunic acid — relevant to its likely-poor membrane permeability. Its oleanane skeleton is shared with widespread plant triterpenes such as oleanolic acid and, in the ursane series, ursolic acid; beta-sitosterol is the co-occurring sterol of the same bark.

What isolate signal actually exists is modest and preliminary — antioxidant/anti-inflammatory in vitro ^{2Reference 2Pawar RS · 2005Effect of oleanane triterpenoids from Terminalia arjuna — a cardioprotective drug — on the process of respiratory oxyburstView study →} and a metabolic-receptor result that is mostly computational ^{6Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →}. No human data exist for arjungenin specifically, and in the one cytotoxicity screen that isolated it alongside its siblings, the active molecule was arjunic acid, not arjungenin ^{4Reference 4Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →}. This section is deliberately short because the honest evidence base is short.

What It's Used For

Arjungenin’s pharmacology is early-stage and almost entirely non-human. The load-bearing caveat is the compound-page discipline: what human evidence exists for arjuna is for the whole bark extract, while the arjungenin-specific data are a handful of in-vitro and in-silico studies.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is isolate-level in-vitro or in-silico work; none rests on human data, so the scores are low by design.

01Antioxidant / Anti-InflammatoryShaky28%In-vitro isolate: free-radical scavenging + neutrophil hypochlorous-acid inhibition ^{2Reference 2Pawar RS · 2005Effect of oleanane triterpenoids from Terminalia arjuna — a cardioprotective drug — on the process of respiratory oxyburstView study →}

02Metabolic / FXR AgonismShaky22%In-silico docking + one 3T3-L1 adipocyte study ^{6Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →}

03Neuroprotective / AChE (In-Silico)Shaky16%Molecular docking among oleanane triterpenes; no wet-lab isolate result ^{7Reference 7Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}

Mechanisms

The load-bearing honesty is that the antioxidant row is the only wet-lab isolate result; the FXR and AChE rows are largely computational, and the CYP row is a useful negative — arjungenin itself did not inhibit the major drug-metabolising enzymes even though whole arjuna extract did.

Pharmacokinetics

There is no human or animal pharmacokinetic dataset for arjungenin — no absorption, Cmax, half-life or oral bioavailability figure exists for the isolate. What can be said is structural and comparative: arjungenin is a large, highly polar tetrahydroxy triterpene acid, and this class of oleanane sapogenins and saponins is characteristically poorly absorbed orally, which is the standing caveat over every in-vitro and in-silico claim above — the concentrations that scavenge radicals or dock into FXR in a dish may simply not be reachable in plasma after oral arjuna. In the bark much of the molecule is present bound as its glucoside (arjunglucoside I / arjunetin) and would require hydrolysis to release the free sapogenin ^{1Reference 1Honda T et al. · 1976Arjungenin, arjunglucoside I, and arjunglucoside IIView study →}. One useful negative PK-adjacent result: isolated arjungenin did not significantly inhibit CYP3A4, CYP2D6 or CYP2C9 in human liver microsomes, even though the whole bark extract did — so the extract’s drug-interaction potential is not attributable to this molecule ^{5Reference 5Varghese A et al. · 2015In vitroIn vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomesView study →}.

Clinical Trials

There are no clinical trials of isolated arjungenin — it has never been administered to humans as a single compound. Every human study of Terminalia arjuna uses crude stem-bark powder or a water/alcohol extract, within which arjungenin is a minor, largely bound constituent; those trials cannot be attributed to the sapogenin.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits firmly on the plant side of the isolate-vs-plant line. All of arjuna’s human evidence — the heart-failure and angina work, the lipid and antioxidant outcomes — is for the whole stem-bark extract or powder, a complex mixture of triterpene acids, saponins, tannins, flavonoids and sterols, dosed at roughly 500 mg three times daily ^{3Reference 3Kalola J · 2006Extraction and TLC densitometric determination of triterpenoid acids (arjungenin, arjunolic acid) from Terminalia arjuna stem bark without interference of tanninsView study →}. Arjungenin’s own record is three small non-clinical studies: one wet-lab in-vitro antioxidant/anti-inflammatory result on the isolate ^{2Reference 2Pawar RS · 2005Effect of oleanane triterpenoids from Terminalia arjuna — a cardioprotective drug — on the process of respiratory oxyburstView study →}, one in-silico-plus-adipocyte metabolic study ^{6Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →}, and one docking study ^{7Reference 7Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}. Even where the isolate was purified alongside its siblings and screened for cytotoxicity, the active compound was arjunic acid, not arjungenin ^{4Reference 4Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →}. The correct framing is therefore: a well-used botanical with a genuine clinical reputation, and a minor constituent molecule whose independent contribution is essentially uncharacterised.

Prevalence in Nature

Arjungenin is, in practical terms, an arjuna-bark molecule. It was first isolated from the stem bark of Terminalia arjuna (Combretaceae) ^{1Reference 1Honda T et al. · 1976Arjungenin, arjunglucoside I, and arjunglucoside IIView study →}, and quantitative analysis of that bark puts it at roughly 0.3% of dry weight (0.324% w/w reported), alongside arjunolic acid at about 0.5% — the two being the measurable oleanane triterpene acids of the bark, within a total triterpenoid fraction under 1% ^{3Reference 3Kalola J · 2006Extraction and TLC densitometric determination of triterpenoid acids (arjungenin, arjunolic acid) from Terminalia arjuna stem bark without interference of tanninsView study →}. Much of it occurs bound as its C-28 glucoside saponins rather than as the free aglycone ^{1,8Reference 1Honda T et al. · 1976Arjungenin, arjunglucoside I, and arjunglucoside IIView study →Reference 8Vyas P et al. · 2025UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna treeView study →}. It is reported more sparingly from other Terminalia / Combretaceae species, but arjuna is the source that matters and the only one with a real quantitative figure.

In the plant, arjungenin is part of a scaffold-selective saponin pathway: the UDP-glucosyltransferase UGT73FB1 glucosylates oleanane aglycones at the C-28 carboxyl to build the bark’s triterpenoid glucosyl esters, though arjungenin is converted to arjunglucoside I comparatively inefficiently, which may be why arjunetin and arjunglucoside II (from arjunic and arjunolic acids) accumulate to higher levels in the bark ^{8Reference 8Vyas P et al. · 2025UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna treeView study →}. This is plant biochemistry, not human pharmacology, and should not be read as such.

Discovery & Synthesis

Arjungenin was first isolated and characterised in 1976 by Tadashi Honda, Tatsushi Murae and co-workers (University of Tokyo), who reported it together with the two new triterpene glucosides arjunglucoside I and arjunglucoside II from Terminalia arjuna bark and assigned its structure as 2α,3β,19α,23-tetrahydroxyolean-12-en-28-oic acid ^{1Reference 1Honda T et al. · 1976Arjungenin, arjunglucoside I, and arjunglucoside IIView study →}. The name marks its origin — the arjun tree — in the botanical-sapogenin tradition (compare arjunolic and arjunic acids). Its close structural relatives arjunolic acid and arjunic acid, and the saponins arjunetin and the arjunglucosides, were mapped out in the same body of Indian and Japanese phytochemistry.

Manufacture today is entirely by extraction from arjuna bark, not synthesis — arjungenin is obtained (often after acid hydrolysis of the bark saponins to free the aglycone) as a research reference compound rather than a commercial product; no total synthesis is in routine use and there is no meaningful market for the pure molecule beyond analytical standards.

Patents: not yet researched.

Toxicity & Safety

Arjungenin carries a low flag. There is no isolate-specific toxicity signal in the small literature that exists: the one study that measured cytotoxicity found arjungenin unremarkable (activity belonged to arjunic acid) ^{4Reference 4Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →}, and the adipocyte study reported no cytotoxicity up to 150 µM ^{6Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →}. This is consistent with the generally low acute toxicity of dietary oleanane triterpenes — but the reassurance is shallow, because no dedicated safety, repeat-dose, genotoxicity or reproductive study of isolated arjungenin has been done, and safety should never be inferred from absence of data.

A useful data point on interactions: isolated arjungenin did not significantly inhibit CYP3A4, CYP2D6 or CYP2C9 in human liver microsomes, so it is unlikely to be the driver of arjuna’s own CYP-inhibitory (drug-interaction) potential, which tracks the whole extract instead ^{5Reference 5Varghese A et al. · 2015In vitroIn vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomesView study →}. No reproductive or developmental data exist for the isolate; any pregnancy/lactation judgement belongs to the arjuna herb page, where intake is actually decided, not to this molecule page.

Safety at a Glance

✅ Low / no toxicity

• No isolate toxicity signal. The cytotoxicity screen found arjungenin unremarkable, and adipocyte work showed no cytotoxicity to 150 µM ^{4,6Reference 4Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →Reference 6T MM et al. · 2020In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytesView study →}.
• Unlikely to drive CYP drug interactions. Isolated arjungenin did not significantly inhibit CYP3A4/2D6/2C9, unlike the whole bark extract ^{5Reference 5Varghese A et al. · 2015In vitroIn vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomesView study →}.
• Safety data are essentially absent. No dedicated repeat-dose, genotoxicity or reproductive study of the isolate exists — low toxicity is inferred, not demonstrated.
• Judge exposure at the herb level. Real-world intake is whole arjuna bark; pregnancy/lactation and dosing decisions belong to the arjuna herb page, not to this molecule.

Dosage

There is no established or recommended dose for isolated arjungenin — it has never been administered to people as a single compound, and every cited figure above is an in-vitro or in-silico concentration, not a human dose. Real-world exposure is through whole arjuna bark: traditional and clinical use is bark powder or a water/alcohol extract, typically around 500 mg three times daily, or a 750 mg twice-daily standardised water extract in the heart-failure trials ^{3Reference 3Kalola J · 2006Extraction and TLC densitometric determination of triterpenoid acids (arjungenin, arjunolic acid) from Terminalia arjuna stem bark without interference of tanninsView study →} — within which arjungenin is a minor (~0.3% of bark), largely bound constituent. These are botanical-extract research figures, not a personal recommendation, and none of them is a dose of arjungenin.

References

1. Honda T, Murae T, Tsuyuki T, Takahashi T, Sawai M (1976). Arjungenin, arjunglucoside I, and arjunglucoside II. A new triterpene and new triterpene glucosides from Terminalia arjuna. Bulletin of the Chemical Society of Japan. https://doi.org/10.1246/bcsj.49.3213
2. Pawar RS, Bhutani KK (2005). Effect of oleanane triterpenoids from Terminalia arjuna — a cardioprotective drug — on the process of respiratory oxyburst. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/15957375/
3. Kalola J, Rajani M (2006). Extraction and TLC densitometric determination of triterpenoid acids (arjungenin, arjunolic acid) from Terminalia arjuna stem bark without interference of tannins. Chromatographia. https://doi.org/10.1365/s10337-006-0772-3
4. Saxena M, Faridi U, Mishra R, Gupta MM, Darokar MP, Srivastava SK, Singh D, Luqman S, Khanuja SP (2007). Cytotoxic agents from Terminalia arjuna. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/18008199/
5. Varghese A, Savai J, Pandita N, Gaud R (2015). In vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomes. Toxicology Reports. https://pubmed.ncbi.nlm.nih.gov/28962416/
6. T MM, T A, P BK, et al. (2020). In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytes. Computational Biology and Chemistry. https://pubmed.ncbi.nlm.nih.gov/31767507/
7. Stępnik K, Kukula-Koch W, Płaziński W (2023). Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosides. Biomolecules. https://pubmed.ncbi.nlm.nih.gov/37759757/
8. Vyas P, Srivastava P, Srivastava G, Kumar A, Garg A, C H R, Ghosh S (2025). UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna tree. The Plant Journal. https://pubmed.ncbi.nlm.nih.gov/40227097/

View all 8 references▾